Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 5/20 | 0.46 |
| ▸ | MAPK10 | P53779 | 5/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.46 |
| ▸ | KDR | P35968 | 2/20 | 0.41 |
| ▸ | MAP2K4 | P45985 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | RORC | P51449 | 6/20 | 0.40 |
| ▸ | RARG | P13631 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | TTK | P33981 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6369498 | 0.91 | MAP2K4 (0.49) | MAPK8MAPK10MAPK14MAP2K4ALDH1A1 | |
| SCHEMBL6369555 | 0.91 | MAPK8 (0.47) | MAPK8MAPK10MAPK14MAP2K4RORC | |
| SCHEMBL22801748 | 0.83 | MAP2K4 (0.52) | KDRMAP2K4ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL6929954 | 0.81 | TTK (0.41) | MAPK8MAPK10MAPK14MAP2K4SMN1; SMN2 | |
| SCHEMBL6370625 | 0.81 | MAPK8 (0.51) | MAPK8MAPK10MAPK14MAP2K4ALDH1A1 | |
| SCHEMBL6370071 | 0.80 | MAP2K4 (0.46) | MAPK8MAPK10MAPK14MAP2K4ALDH1A1 | |
| SCHEMBL22801648 | 0.79 | MAP2K4 (0.52) | MAPK14MAP2K4ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL6370068 | 0.79 | MAP2K4 (0.48) | MAPK10MAPK14MAP2K4ALDH1A1HPGD | |
| SCHEMBL6370569 | 0.79 | MAP2K4 (0.44) | MAPK8MAPK10MAPK14MAP2K4ALDH1A1 | |
| SCHEMBL6370930 | 0.76 | ELANE (0.48) | MAP2K4ALDH1A1HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050113370-A1 | Therapeutic substituted indazole derivatives | ASTRAZENECA AB (SE) | 2005-05-26 | — | — | US | disclosed |
| EP-1476432-A1 | THERAPEUTIC SUBSTITUTED INDAZOLE DERIVATIVES | AstraZeneca AB (SE) | 2004-11-17 | — | — | EP | disclosed |
| WO-2003068754-A1 | THERAPEUTIC SUBSTITUTED INDAZOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113370-A1 | Therapeutic substituted indazole derivatives | NR4A3, CBR3, NR3C2 | MAPK8 1582/4885MAPK10 2059/4885MAPK14 2226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.